Small cell lung cancer (SCLC) is a fast-growing cancer that develops in cells within the lung. A range of medical tests and procedures are available to help doctors diagnose SCLC and create an ...

The latest update is out from bioAffinity Technologies, Inc. ( ($BIAF) ). On September 3, 2025, bioAffinity Technologies announced that U.S.

The test is based on what Veracyte calls "field of injury" technology, which catches molecular changes in the lining of the respiratory tract to indicate cancer or cancer-related changes in the lung.

Lung cancer is the leading cause of cancer deaths in America, and catching it early is vital. That's exactly what a low-dose CT scan does, but only one-in-10 people at higher risk take advantage ...

RELATED: With positive early data, Veracyte eyes 2021 launch for nasal-swab lung cancer test A nasal swab would, of course, be much more accessible.

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal ...

Researcher suggest new test approach could be used to verify early lung cancer in patients who test positive by computed tomography.

A new economic study found that adding CyPath® Lung, bioAffinity Technologies’ noninvasive test for detection of early-stage lung cancer, to the standard of care for Medicare patients with a ...

Now, all five Biodesix blood-based lung diagnostic tests within the Nodify Lung Nodule Risk Assessment testing strategy and IQLung™ strategy for lung cancer patients are now covered by Medicare.

Injured and unusable lungs were restored with respirators and pig blood. The procedure one day may increase the supply of organs for transplant.